Intercardia/Astra Merck to collaborate on beta blocker bucindolol for treatment of CHF.
Executive Summary
INTERCARDIA/ASTRA MERCK TO COLLABORATE ON BETA BLOCKER BUCINDOLOL in a development and marketing agreement announced Dec. 5. Bucindolol, which blocks both beta one and beta two receptors, is being developed by Intercardia for treatment of moderate to severe congestive heart failure.